Close Menu

NEW YORK – PerkinElmer said after the close of the market on Tuesday that its revenues for the second quarter increased a fraction of 1 percent year over year, while its Diagnostics segment slipped 2 percent.

For the three months ended April 5, the Waltham, Massachusetts-based company posted total revenues of $652.4 million compared to $648.7 million a year ago, and slightly below the consensus Wall Street estimate of $652.7 million. Organic revenues were down about 1 percent, PerkinElmer said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

European regulators have begun a rolling review of Russia's Sputnik V SARS-CoV-2 vaccine, Reuters reports.

Science reports that Science Foundation Ireland is seeking annual budget increases.

According to the Financial Times, a UK university group is pushing Elsevier to lower its journal fees.

In Nature this week: satellite tracking and genome sequencing combination used to examine migration patterns of peregrine falcons, and more.